Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study-Reference-Cited by-同舟云学术

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Published:2021-08 Issue:10301 Volume:398 Page:665-674
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Usmani Saad Z,Garfall Alfred L,van de Donk Niels W C J,Nahi Hareth,San-Miguel Jesus F,Oriol Albert,Rosinol Laura,Chari Ajai,Bhutani Manisha,Karlin Lionel,Benboubker Lotfi,Pei Lixia,Verona Raluca,Girgis Suzette,Stephenson Tara,Elsayed Yusri,Infante Jeffrey,Goldberg Jenna D,Banerjee Arnob,Mateos María-Victoria,Krishnan Amrita

Funder

Janssen Research and Development LLC

Publisher

Elsevier BV

Subject

General Medicine

Reference20 articles.

1. Proteasome inhibitors in multiple myeloma: 10 years later;Moreau;Blood,2012

2. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;Kumar;Leukemia,2014

3. CD38 antibodies in multiple myeloma: back to the future;van de Donk;Blood,2018

4. Multiple myeloma: patient outcomes in real-world practice;Yong;Br J Haematol,2016

5. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy;Gandhi;Leukemia,2019

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells;Nature Cancer;2024-09-11

2. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement;Expert Opinion on Biological Therapy;2024-09

3. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies;The Lancet Haematology;2024-09

4. Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Polymeric PD1/PDL1 Bispecific Antibody Enhances Immune Checkpoint Blockade Therapy;Materials Today Bio;2024-09